Bone-related complications and quality of life in advanced breast cancer: Results from a randomized phase III trial of denosumab versus zoledronic acid

Clinical Cancer Research

Volumn 18, Issue 17, 2012, Pages 4841-4849

  Martin, Miguel ^a   Bell, Richard ^b   Bourgeois, Hugues ^c   Brufsky, Adam ^d   Diel, Ingo ^e   Eniu, Alexandru ^f   Fallowfield, Lesley ^g   Fujiwara, Yasuhiro ^h   Jassem, Jacek ⁱ   Paterson, Alexander H G ^j   Ritchie, Diana ^k   Steger, Günther G ^l   Stopeck, Alison ^m   Vogel, Charles ⁿ   Fan, Michelle ^o   Jiang, Qi ^e   Chung, Karen ^o   Dansey, Roger ^o   Braun, Ada ^o  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b Andrew Love Cancer Centre   (Australia)

^c CENTRE JEAN BERNARD   (France)

^d UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^e Onkologische Schwerpunkt Praxis   (Germany)

^f THE ONCOLOGY INSTITUTE PROF DR ION CHIRICUTA   (Romania)

^g UNIVERSITY OF SUSSEX   (United Kingdom)

^h NATIONAL CANCER CENTER HOSPITAL   (Japan)

ⁱ MEDICAL UNIVERSITY OF GDANSK   (Poland)

^j TOM BAKER CANCER CENTRE   (Canada)

^k BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^l UNIVERSITY OF VIENNA   (Austria)

^m UNIVERSITY OF ARIZONA   (United States)

ⁿ UNIVERSITY OF MIAMI   (United States)

^o AMGEN INC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DENOSUMAB; PLACEBO; ZOLEDRONIC ACID;

ADULT; AGED; ARTHRALGIA; ARTICLE; BACKACHE; BONE DISEASE; BONE METASTASIS; BONE PAIN; BREAST CANCER; CANCER RADIOTHERAPY; CHILL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FLU LIKE SYNDROME; HUMAN; HYPERCALCEMIA; MAJOR CLINICAL STUDY; MALAISE; NEPHROTOXICITY; PARALLEL DESIGN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKELETAL RELATED EVENT; THORAX PAIN;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; BONE NEOPLASMS; BREAST NEOPLASMS; DIPHOSPHONATES; DRUG TOXICITY; FEMALE; HUMANS; IMIDAZOLES; MIDDLE AGED; NEOPLASM STAGING; QUALITY OF LIFE; RANK LIGAND;

EID: 84865753315     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-3310     Document Type: Article

References (38)

1. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006;12:6243s-9s.
2. Costa L, Badia X, Chow E, Lipton A, Wardley A. Impact of skeletal complications on patients' quality of life, mobility, and functional independence. Support Care Cancer 2008;16:879-89.
3. Weinfurt KP, Castel LD, Li Y, Timbie JW, Glendenning GA, Schulman KA. Health-related quality of life among patients with breast cancer receiving zoledronic acid orpamidronate disodium for metastatic bone lesions. Med Care 2004;42:164-75.
4. Pockett RD, Castellano D, McEwan P, Oglesby A, Barber BL, Chung K. The hospital burden of disease associated with bone metastases and skeletal-related events in patients with breast cancer, lung cancer, or prostate cancer in Spain. Eur J Cancer Care (Engl) 2010;19:755-60.
5. Wardley A, Davidson N, Barrett-Lee P, Hong A, Mansi J, Dodwell D, et al. Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration. Br J Cancer 2005;92:1869-76.
6. Body JJ, Diel IJ, Bell R, Pecherstorfer M, Lichinitser MR, Lazarev AF, et al. Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain 2004;111:306-12.
7. Aapro M, Abrahamsson PA, Body JJ, Coleman RE, Colomer R, Costa L, et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 2008;19: 420-32.
8. Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 2001;7:377-87.
9. Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 2003;98:1735-44.
10. Rosen LS, Gordon D, Tchekmedyian NS, Yanagihara R, Hirsh V, Krzakowski M, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial. Cancer 2004;100:2613-21.
11. Novartis Pharmaceuticals Corporation. Zometa (zoledronic acid) prescribing information. East Hanover, NJ; 2011.
12. Hofbauer LC, Neubauer A, Heufelder AE. Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases. Cancer 2001;92:460-70.
13. Stopeck A, Lipton A, Body JJ, Steger GG, Tonkin KS, de Boer R, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010;28:5132-9.
14. Fizazi K, Carducci M, Smith M, Damiao R, Brown J, Karsh L, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011;377:813-22.
15. Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011;29:1125-32.
16. Kohno N, Aogi K, Minami H, Nakamura S, Asaga T, Iino Y, et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 2005;23: 3314-21.
17. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Statistical review and evaluation of zometa, summary basis of approval, February 14, 2002.
18. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Statistical review and evaluation of aredia, summary basis of approval. July 12, 1996.
19. Webster K, Cella D, Yost K. The functional assessment of chronic illness therapy (FACIT) measurement system: properties, applications, and interpretation. Health Qual Life Outcomes 2003;1:79.
20. Eton DT, Cella D, Yost KJ, Yount SE, Peterman AH, Neuberg DS, et al. A combination of distribution- and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale. J Clin Epidemiol 2004;57:898-910.
21. Chung K, Barlev A, Braun A, Qian Y, Zagari M. Development of the analgesic quantification algorithm (AQA): a new scale to assess analgesic use. Eur J Can Suppl 2009;7:186 (abstr P-3037).
22. Brady MJ, Cella DF, Mo F, Bonomi AE, Tulsky DS, Lloyd SR, et al. Reliability and validity of the functional assessment of cancer therapy-breast quality-of-life instrument. J Clin Oncol 1997;15:974-86.
23. Rosen LS, Gordon D, Tchekmedyian S, Yanagihara R, Hirsh V, Krzakowski M, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial - the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 2003;21:3150-7.
24. Novartis Pharmaceuticals Corporation. Aredia (pamidronate disodium for injection) full prescribing information. East Hanover, NJ; 2008.
25. Stopeck A, Rader M, Henry DH, Danese M, Cong Z, Halperin M, et al. Cost-effectiveness of denosumab versus zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States. J Med Econ 2012;15:712-23.
26. Diel IJ, Bergner R, Grotz KA. Adverse effects of bisphosphonates: current issues. J Support Oncol 2007;5:475-82.
27. Perazella MA, Markowitz GS. Bisphosphonate nephrotoxicity. Kidney Int 2008;74:1385-93.
28. Tabrizi MA, Tseng CM, Roskos LK. Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov Today 2006;11:81-8.
29. Amgen Inc. XGEVA (denosumab injection) Full prescribing information. Thousand Oaks, CA, USA; 2012.
30. Launay-Vacher V, Gligorov J, Le Tourneau C, Janus N, Spano JP, Ray-Coquard I, et al. Prevalence of renal insufficiency in breast cancer patients and related pharmacological issues. Breast Cancer Res Treat 2010;124:745-53.
31. Thadhani R, Pascual M, Bonventre JV. Acute renal failure. N Engl J Med 1996;334:1448-60.
32. Adami S, Bhalla AK, Dorizzi R, Montesanti F, Rosini S, Salvagno G, et al. The acute-phase response after bisphosphonate administration. Calcif Tissue Int 1987;41:326-31.
33. Russell RG, Xia Z, Dunford JE, Oppermann U, Kwaasi A, Hulley PA, et al. Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. Ann N Y Acad Sci 2007;1117:209-57.
34. Diel IJ. Bisphosphonates in breast cancer patients with bone metastases. Breast Care (Basel) 2010;5:306-11.
35. Oglesby A, Sherif B, Odom D, Leahy M, Qian Y. Time and costs associated with preparing and administering zoledronic acid in patients with breast or prostate cancer and metastatic bone disease. Commun Oncol 2009;6:494-502.
36. Dawood S, Broglio K, Ensor J, Hortobagyi GN, Giordano SH. Survival differences among women with de novo stage IV and relapsed breast cancer. Ann Oncol 2010;21:2169-74.
37. Jung SY, Rosenzweig M, Sereika SM, Linkov F, Brufsky A, Weissfeld JL. Factors associated with mortality after breast cancer metastasis. Cancer Causes Control 2012;23:103-12.
38. Harris K, Chow E, Zhang L, Velikova G, Bezjak A, Wu J, et al. Patients' and health care professionals' evaluation of health-related quality of life issues in bone metastases. Eur J Cancer 2009;45:2510-8.